BrainsWay (NASDAQ:BWAY - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $16.00 price objective on the stock. HC Wainwright's price target points to a potential upside of 40.11% from the company's current price.
BrainsWay Trading Down 2.6%
Shares of BWAY traded down $0.31 during mid-day trading on Monday, hitting $11.42. The company's stock had a trading volume of 27,223 shares, compared to its average volume of 66,664. The company's 50-day moving average is $9.46 and its 200-day moving average is $9.79. BrainsWay has a 52-week low of $5.67 and a 52-week high of $12.00. The firm has a market capitalization of $215.64 million, a price-to-earnings ratio of 114.21 and a beta of 1.32.
BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $11.54 million for the quarter, compared to the consensus estimate of $11.45 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. As a group, sell-side analysts predict that BrainsWay will post 0.08 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Lazard Asset Management LLC purchased a new position in BrainsWay in the fourth quarter worth $44,000. GAMMA Investing LLC boosted its position in shares of BrainsWay by 720.7% in the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock worth $89,000 after purchasing an additional 8,216 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in BrainsWay during the 1st quarter worth $111,000. Trexquant Investment LP purchased a new stake in BrainsWay in the first quarter valued at about $129,000. Finally, Sei Investments Co. acquired a new stake in BrainsWay in the fourth quarter worth about $149,000. Hedge funds and other institutional investors own 30.11% of the company's stock.
About BrainsWay
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Recommended Stories
Before you consider Brainsway, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainsway wasn't on the list.
While Brainsway currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
